BMS-284756对沙眼衣原体及肺炎衣原体近期临床分离株的体外活性
In vitro activities of BMS-284756 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.
作者信息
Malay Sheila, Roblin Patricia M, Reznik Tamara, Kutlin Andrei, Hammerschlag Margaret R
机构信息
Division of Infectious Diseases, Department of Pediatrics, State University of New York Downstate Medical Center, Brooklyn, New York 11203-2098, USA.
出版信息
Antimicrob Agents Chemother. 2002 Feb;46(2):517-8. doi: 10.1128/AAC.46.2.517-518.2002.
Abstract
The in vitro activities of BMS-284756 (a novel des-fluoroquinolone), levofloxacin, moxifloxacin, and clarithromycin were tested against 5 strains of Chlamydia trachomatis and 20 isolates of Chlamydia pneumoniae. The MIC at which 90% of the isolates were inhibited and the minimal bactericidal concentration at which 90% of the isolates were killed by BMS-284756 for all isolates of C. pneumoniae and C. trachomatis was 0.015 microg/ml (range, 0.015 to 0.03 microg/ml). BMS-284756 was the most active quinolone tested.
摘要
测试了新型去氟喹诺酮BMS - 284756、左氧氟沙星、莫西沙星和克拉霉素对5株沙眼衣原体和20株肺炎衣原体的体外活性。对于所有肺炎衣原体和沙眼衣原体分离株，BMS - 284756抑制90%分离株的最低抑菌浓度（MIC）以及杀灭90%分离株的最低杀菌浓度均为0.015微克/毫升（范围为0.015至0.03微克/毫升）。BMS - 284756是所测试的喹诺酮类药物中活性最强的。
相似文献
1
In vitro activities of BMS-284756 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.BMS-284756对沙眼衣原体及肺炎衣原体近期临床分离株的体外活性
Antimicrob Agents Chemother. 2002 Feb;46(2):517-8. doi: 10.1128/AAC.46.2.517-518.2002.
2
In vitro activity of garenoxacin against recent clinical isolates of Chlamydia pneumoniae.加替沙星对近期肺炎衣原体临床分离株的体外活性
Int J Antimicrob Agents. 2003 Jun;21(6):578-80. doi: 10.1016/s0924-8579(03)00061-x.
3
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone antibiotic, against Chlamydia trachomatis and Chlamydia pneumoniae.新型非氟喹诺酮类抗生素奈诺沙星对沙眼衣原体和肺炎衣原体的体外活性
Antimicrob Agents Chemother. 2014;58(3):1800-1. doi: 10.1128/AAC.02263-13. Epub 2013 Dec 23.
4
Comparative in vitro activity of garenoxacin against Chlamydia spp.加替沙星对衣原体属的体外活性比较
J Antimicrob Chemother. 2002 Sep;50(3):407-10. doi: 10.1093/jac/dkf145.
5
In-vitro activity of gatifloxacin against Chlamydia trachomatis and Chlamydia pneumoniae.加替沙星对沙眼衣原体和肺炎衣原体的体外活性。
J Antimicrob Chemother. 1999 Oct;44(4):549-51. doi: 10.1093/jac/44.4.549.
6
In vitro activities of gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae.吉米沙星（SB 265805，LB20304）对近期肺炎衣原体临床分离株的体外活性。
Antimicrob Agents Chemother. 1999 Nov;43(11):2806-7. doi: 10.1128/AAC.43.11.2806.
7
In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp.新型氟喹诺酮类药物AM - 1155对衣原体属的体外和体内活性
Antimicrob Agents Chemother. 1997 Jun;41(6):1331-4. doi: 10.1128/AAC.41.6.1331.
8
In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.利福霉素衍生物ABI-1648（利福拉齐，KRM-1648）、ABI-1657和ABI-1131对沙眼衣原体及肺炎衣原体近期临床分离株的体外活性。
Antimicrob Agents Chemother. 2003 Mar;47(3):1135-6. doi: 10.1128/AAC.47.3.1135-1136.2003.
9
In vitro activity of CEM-101, a new fluoroketolide antibiotic, against Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae.新型氟喹诺酮类抗生素 CEM-101 对沙眼衣原体和肺炎衣原体（衣原体属）的体外活性。
Antimicrob Agents Chemother. 2010 Mar;54(3):1358-9. doi: 10.1128/AAC.01343-09. Epub 2009 Dec 28.
10
In vitro activity of a novel diaminopyrimidine compound, iclaprim, against Chlamydia trachomatis and C. pneumoniae.新型二氨基嘧啶化合物伊克拉普对沙眼衣原体和肺炎衣原体的体外活性
Antimicrob Agents Chemother. 2004 May;48(5):1885-6. doi: 10.1128/AAC.48.5.1885-1886.2004.
引用本文的文献
1
Recombinant Human Peptidoglycan Recognition Proteins Reveal Antichlamydial Activity.重组人肽聚糖识别蛋白显示出抗衣原体活性。
Infect Immun. 2016 Jun 23;84(7):2124-2130. doi: 10.1128/IAI.01495-15. Print 2016 Jul.
2
Mycoplasma genitalium: should we treat and how?生殖道支原体：我们是否应该治疗以及如何治疗？
Clin Infect Dis. 2011 Dec;53 Suppl 3(Suppl 3):S129-42. doi: 10.1093/cid/cir702.
3
Serine-to-asparagine substitution in the GyrA gene leads to quinolone resistance in moxifloxacin-exposed Chlamydia pneumoniae.GyrA基因中的丝氨酸到天冬酰胺的替换导致暴露于莫西沙星的肺炎衣原体对喹诺酮耐药。
Antimicrob Agents Chemother. 2005 Jan;49(1):406-7. doi: 10.1128/AAC.49.1.406-407.2005.
4
In vitro activities of garenoxacin and levofloxacin against Chlamydia pneumoniae are not affected by presence of Mycoplasma DNA.加替沙星和左氧氟沙星对肺炎衣原体的体外活性不受支原体DNA存在的影响。
Antimicrob Agents Chemother. 2004 Jun;48(6):2081-4. doi: 10.1128/AAC.48.6.2081-2084.2004.
5
Inhibitory activities of quinolones against DNA gyrase of Chlamydia pneumoniae.喹诺酮类药物对肺炎衣原体DNA旋转酶的抑制活性。
Antimicrob Agents Chemother. 2003 Jul;47(7):2327-9. doi: 10.1128/AAC.47.7.2327-2329.2003.
6
In vitro activity of a new antibiotic, NVP-PDF386 (VRC4887), against Chlamydia pneumoniae.新型抗生素NVP-PDF386（VRC4887）对肺炎衣原体的体外活性
Antimicrob Agents Chemother. 2003 Apr;47(4):1447-8. doi: 10.1128/AAC.47.4.1447-1448.2003.
7
In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas.加替沙星（BMS - 284756）及其他抗菌药物对人型支原体和脲原体的体外敏感性及杀菌活性
Antimicrob Agents Chemother. 2003 Jan;47(1):161-5. doi: 10.1128/AAC.47.1.161-165.2003.
本文引用的文献
1
In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae.T-3811ME（BMS-284756）对肺炎支原体的体外和体内疗效
Antimicrob Agents Chemother. 2001 Jan;45(1):312-5. doi: 10.1128/AAC.45.1.312-315.2001.
2
Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756.新型去氟（6）喹诺酮BMS-284756的抗菌谱
Antimicrob Agents Chemother. 2000 Dec;44(12):3351-6. doi: 10.1128/AAC.44.12.3351-3356.2000.
3
Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae.莫西沙星治疗肺炎衣原体所致社区获得性肺炎的微生物学疗效。
Int J Antimicrob Agents. 2000 Jul;15(2):149-52. doi: 10.1016/s0924-8579(00)00157-6.
4
Activity of gemifloxacin and other new quinolones against Chlamydia pneumoniae: a review.吉米沙星及其他新型喹诺酮类药物对肺炎衣原体的活性：综述
J Antimicrob Chemother. 2000 Apr;45 Suppl 1:35-9. doi: 10.1093/jac/45.suppl_3.35.
5
Microbiological efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae.左氧氟沙星治疗肺炎衣原体所致社区获得性肺炎的微生物学疗效。
Antimicrob Agents Chemother. 2000 May;44(5):1409. doi: 10.1128/AAC.44.5.1409-1409.2000.
6
In vitro activity of grepafloxacin against Haemophilus influenzae and Moraxella catarrhalis.
Eur J Clin Microbiol Infect Dis. 1998 Apr;17(4):293-5. doi: 10.1007/BF01699991.
7
1998 guidelines for treatment of sexually transmitted diseases. Centers for Disease Control and Prevention.1998年性传播疾病治疗指南。疾病控制和预防中心。
MMWR Recomm Rep. 1998 Jan 23;47(RR-1):1-111.
8
Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia.阿奇霉素对成人和儿童社区获得性肺炎患者肺炎衣原体分离株的微生物学疗效及肺炎衣原体分离株对阿奇霉素的敏感性
Antimicrob Agents Chemother. 1998 Jan;42(1):194-6. doi: 10.1128/AAC.42.1.194.
9
Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.格雷帕沙星、环丙沙星、氧氟沙星和氟罗沙星的抗菌活性。
J Chemother. 1997 Feb;9(1):9-16. doi: 10.1179/joc.1997.9.1.9.
10
Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae.肺炎衣原体所致感染的抗菌药敏性及治疗
Antimicrob Agents Chemother. 1994 Sep;38(9):1873-8. doi: 10.1128/AAC.38.9.1873.
Zotero 插件